Immutep and Lonza sign agreement for cell line selection, cell banking and process development of ImmuFact(R) IMP321

13-Apr-2012 - Switzerland

Immutep and Lonza announced an agreement for cell line selection, master cell banking and process development of ImmuFact(R) IMP321. Lonza will initiate the process development for Immutep’s lead product, using Immutep's newly-developed proprietary cell lines. Immutep announced Phase I/II results for IMP321 in an oral presentation at ASCO (American Society of Clinical Oncology conference) in 2010 describing its use in a chemo-immunotherapy protocol in first-line metastatic breast cancer.
 
“We are pleased to support Immutep’s development initiatives,” said Janet White, head of Lonza development services. “This partnership directly reflects Lonza’s commitment to emerging biotechnology innovation through its clinical milestones.”  
 
IMP321 (LAG-3Ig) has potential for the treatment of advanced cancer in combination with standard first-line chemotherapy. IMP321 is an antigen presenting cell (APC) activator. Tumour-specific memory CD8 T cells are activated by these APC and contribute to tumour regression. 

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...